Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy
Conclusion: First-line systemic therapy for favorable risk mRCC patients with a single agent resulted in relatively longer PFS and OS. A longer duration of first-line treatment and lung only metastases are correlated with longer OS.Urol Int
Source: Urologia Internationalis - Category: Urology & Nephrology Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology